PAVmed Inc. (PAVM)
Stock Price:
$1.93 USD
0.04 (2.12%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $1.97 +0.04 (2.07%) Oct 27, 4:58 PM
Key Info
| Market Cap |
96.70M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-29.38M |
| Shares Out |
50.10M |
| EPS (ttm) |
-0.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$1.93 |
| Previous Close |
$1.89 |
| Change ($) |
0.04 |
| Change (%) |
2.12% |
| Day's Open |
1.87 |
| Day's Range |
1.85 - 1.95 |
| Day's Volume |
339,131 |
| 52-Week Range |
0.81 - 3.45 |
More Stats
| Market Cap |
96.70M |
| Enterprise Value |
106.12M |
| Earnings Date (est) |
Nov 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
50.10M |
| Float |
39.77M |
| EPS (basic) |
-0.74 |
| EPS (diluted) |
-0.77 |
| FCF / Share |
-0.37 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.56M |
| Short Ratio |
5.90 |
| Short % of Float |
8.94% |
| Beta |
0.03 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
17.73 |
| Revenue |
n/a |
| Operating Income |
-18.10M |
| Net Income |
-29.38M |
| Free Cash Flow |
-16.36M |
| Net Cash |
-9.42M |
| Net Cash / Share |
-0.19 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-141.92% |
| ROE |
-3,048.66% |
| ROIC |
954.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.00*
(159.07% upside)
Low
5.00
Current: $1.93
High
5.00
Target: 5.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -14.30 | -10.56 | -8.03 | -5.65 | -1.78 |
| Net Income | -16.46 | -17.97 | -9.52 | -5.65 | -1.78 |
| Shares Outstanding | 30.20 | 22.28 | 13.50 | 12.97 | 11.28 |
| Earnings Per Share | -0.54 | -0.81 | -0.71 | -0.44 | -0.16 |
| Operating Cash Flow | -13.36 | -8.79 | -6.61 | -4.45 | -1.25 |
| Capital Expenditures | -0.03 | -0.03 | -0.01 | -0.02 | - |
| Free Cash Flow | -13.38 | -8.81 | -6.61 | -4.48 | -1.25 |
| Cash & Equivalents | 6.22 | 8.22 | 1.54 | 0.59 | 0.77 |
| Total Debt | 8.14 | 7.90 | 1.94 | - | - |
| Net Cash / Debt | -1.92 | 0.32 | -0.41 | 0.59 | 0.77 |
| Assets | 7.24 | 8.50 | 1.64 | 0.87 | 1.21 |
| Liabilities | 11.88 | 10.97 | 4.49 | 1.19 | 0.58 |
| Book Value | -3.82 | -2.31 | -2.85 | -0.32 | 0.63 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
PAVmed Inc. |
| Country |
United States |
| Employees |
15 |
| CEO |
Lishan Aklog |
Stock Information
| Ticker Symbol |
PAVM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: PAVM |
| IPO Date |
April 28, 2016 |
Description
PAVmed operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.